Company description

Axonics Modulation Technologies, Inc., with the ticker symbol AXNX, is a medical technology company that aims to improve the lives of patients suffering from underactive bladder, overactive bladder, and fecal incontinence. The company has developed a novel and innovative technology that provides long-term relief to these patients through an advanced implantable neuromodulation system. Axonics is the first and only company to have received FDA approval for sacral neuromodulation devices for the treatment of these three conditions. The AXNX team is comprised of experienced professionals with a proven track record in medical device development and a passion for bringing innovative therapies to patients. The company's mission is to transform the field of neuromodulation and make a meaningful impact in the lives of patients worldwide. In addition to their impressive product portfolio, Axonics also prioritizes ethical and responsible business practices, including philanthropic efforts to support underprivileged communities. With a strong financial foundation and a commitment to cutting-edge research and development, Axonics Modulation Technologies is poised to continue its success and revolutionize the treatment of bladder and bowel dysfunction.